- RecruitingPhase IV
A clinical study to investigate whether third-line treatments work better as a second-line treatment for people diagnosed with schizophrenia
This UK study looks at whether offering a medication called clozapine sooner helps people with schizophrenia. Clozapine is usually only tried after two other medicines fail. Researchers want to see if using it as a second option eases symptoms faster and improves everyday life, with close safety monitoring throughout.
For: Schizophrenia, schizoaffective disorder or schizophreniform disorderUnited Kingdom · Australia · Austria - RecruitingPHASE4
Biomarkers to Enhance Early Schizophrenia Treatment
This study looks at specific genetic factors and brain scans in young people having their first episode of psychosis. The aim is to see if these factors can help predict who might benefit most from certain medications, like aripiprazole, risperidone, or clozapine.
For: Schizophenia DisorderUnited States · Canada - RecruitingPHASE4
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
This study looks at whether giving an established medication called clozapine earlier to people with schizophrenia, who haven't responded to their first treatment, works better than standard treatments. It aims to see if starting clozapine sooner can prevent more problems.
For: Schizophrenia and Related Disorders · Early Treatment-ResistanceAustria · Germany · Italy - AuthorisedTherapeutic use (Phase IV)
Assessment of clozapine-related immunodeficiency effect in Parkinson's disease patients (CLOZIDPD)
This study looks at how a medicine called clozapine affects the body's infection-fighting system in people with Parkinson's disease. Researchers will check blood levels that show how well the immune system is working before and after taking clozapine for six months.
For: Parkinson's diseaseFrance